• From precision proteomics to precision medicine

    Precision medicine is defined by the NIH as “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person”. Healthcare today, however,  still largely adheres to a one-size-fits-all approach, based on strategies that have been developed for the “average” person, with less consideration of individual differences. That inevitably leads to the questions of why these concepts have yet to be established in clinical practice and what is needed for it to happen? Olink’s vision is to help to drive the implementation of this vitally needed paradigm-shift in global healthcare by providing innovative  and effective tools for protein biomarker discovery and development.

    precision medicine

    Today, Olink’s protein biomarker panels enable rapid, robust identification of protein signatures to:

    • stratify patients
    • predict disease and treatment outcomes
    • understand pathophysiology or discover new drug targets

    We call this “Precision Proteomics”.

    We are continuously developing our platform, offering a wider selection of biomarker assays to enable our customers to cast the net as wide as possible for the discovery of new protein signatures.

    Using protein signatures will likely transform the future of disease diagnosis, treatment, and our understanding of health. We will provide these powerful tools to translate protein biomarker discovery into the clinic. To tailor healthcare to individual patients, Olink aims to be your partner every step of the way on this journey, from precision proteomics to precision diagnostics and the realization of precision medicine.

    Let us share our vision with you!

  • Olink and precision medicine

    Hear what Andrea Ballagi, VP for Sales & Marketing at Olink, had to say about the company’s future role in precision medicine in an interview given at the 2015 Precision Medicine Congress in London: